

Partnership with the Pharmaceutical Industry

With its patient registry, the SCQM Foundation aims to improve patient care and support research in rheumatology by collecting and analysing data related to medication effectiveness and safety.

Financing

To provide this valuable resource for patient care and medical research, we rely on financial support from partners, including the pharmaceutical industry. Pharmaceutical companies financially support the Foundation's running costs and, in exchange, gain access to aggregated data and general insights about medication use, including that of their competitors. Transparency is important to us, so we make details of our financial support available on [our website](#).

Collaboration on Observational Studies

As part of our partnership, pharmaceutical companies may sponsor observational studies using data collected by our registry. These studies must comply with our strict rules of research and receive approval from an independent ethics committee before they can be conducted. Real-world evidence is important, and these studies can help us better understand the impact of various therapies on patient well-being and identify potential safety concerns.

Ethical Conduct

Pharmaceutical companies have no influence over our use of funds, the direction, or operation of the registry. When investigator-initiated studies with SCQM involvement receive independent financial support from pharmaceutical companies, the latter have no role in the study design, in the collection, analysis and interpretation of the data, the writing of the manuscript or any decision to submit the manuscript for publication. All data are kept within our foundation for further research and analysis. Our goal is to provide a valuable resource for medical research while upholding the highest standards of ethical conduct.